The Role of CMAs in Quality by Design (QbD): Quality cannot be tested into a product. It must be designed into it. In the QbD paradigm, Critical Material Attributes (CMAs) are the variables that determine whether that design holds or collapses when raw materials arrive at your dock.
CMA vs. CQA: Understanding the Difference in Pharmaceutical Technology Transfer: Conflating input material attributes with output product characteristics is a quiet but persistent source of scale-up failure.
Risk Evaluation in Biopharmaceutical Technology Transfer: Why a Risk-Based Approach Is Essential for GMP Success. Successful biopharmaceutical technology transfer depends on more than process knowledge.
Tagged : Biopharmaceutical, Compliance, GxP, MSAT, QRM, Quality 4.0, Risk Management, Technology Transfer
Drafting Perfect 483 Responses: The New FDA Guidelines Explained. FDA Form 483 observations are issued when investigators identify conditions that may violate cGMP requirements.
Beyond Documentation: Solving the Tacit Knowledge Gap in Pharmaceutical Tech Transfer: This article discuss why Your Documentation Is Not Enough and How to Institutionalize Expert Know-How. Visit us for more…